Akebia Therapeutics Inc Dossier - Source-backed chat

Akebia Therapeutics Inc

AKBANASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.50

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $0.92Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $254.9M

Enterprise Value $149M

Shares Outstanding 269M diluted

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Akebia Therapeutics is undergoing a critical commercial transition. While its legacy product, Auryxia, faces immediate generic erosion following the entry of Teva's generic in March 2026, the company's long-term growth is anchored by the commercial launch of Vafseo (vadadustat) in the U.S. dialysis market. Vafseo is showing strong early adoption metrics, with a 60% quarter-over-quarter increase in patients and a 28% increase in prescribers in Q1 2026. Backed by a solid cash position of $162.6 million (providing a two-year runway) and an advancing mid-stage rare kidney disease pipeline (including praliciguat in Phase 2 and AKB-9090 in Phase 1), Akebia represents a high-upside biotech opportunity as Vafseo scales toward a $1 billion post-TDAPA market opportunity.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets5 analysts · as of 18 Aug 2026

Low · most bearish analyst$3.00

Mean target$4.20

High · most bullish analyst$6.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$1.5015%

Auryxia revenues erode much faster than anticipated due to aggressive generic pricing from Teva and other entrants. Meanwhile, Vafseo adoption is slowed by cautious rollouts at major dialysis providers or reimbursement friction post-TDAPA. Slower sales growth combined with high R&D expenses for the rare kidney disease pipeline accelerates cash burn, forcing dilutive capital raises.

Base CaseCentral scenario

$4.0060%

Vafseo continues its steady commercial ramp, offsetting the projected decline in Auryxia revenues due to generic competition. The company successfully navigates the transition of Vafseo out of the TDAPA reimbursement period by the end of 2026, maintaining stable volume growth. Pipeline candidates progress on schedule, with key clinical readouts expected in 2027.

Bull CaseUpside scenario

$6.0025%

Vafseo adoption accelerates rapidly across major dialysis organizations (including DaVita and Fresenius), establishing it as the standard of care for CKD-induced anemia. Post-TDAPA pricing parity with ESAs is achieved smoothly, driving Vafseo to peak U.S. sales exceeding $500 million. Concurrently, praliciguat delivers positive Phase 2 data in FSGS, and AKB-097 successfully enters its Phase 2 basket trial, unlocking a high-value rare nephrology pipeline.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong early commercial momentum for Vafseo, with Q1 2026 net product revenues growing to $15.8 million (up 32% YoY).
Robust cash position of $162.6 million as of March 31, 2026, providing at least a two-year operating runway.
Expanding mid-stage pipeline targeting high unmet needs in rare kidney diseases, including praliciguat (Phase 2 FSGS) and AKB-9090 (Phase 1 AKI).
Vafseo's clinical differentiation, with data showing lower risk of death or hospitalization compared to standard-of-care ESAs.

Key Investment Risks

Accelerated revenue decline of Auryxia due to the entry of Teva's generic and other authorized generics.
Reimbursement and pricing risks associated with the expiration of Vafseo's TDAPA status on December 31, 2026.
Execution and clinical trial risks inherent in developing mid-stage pipeline candidates (praliciguat, AKB-097, AKB-9090).

Thesis Invalidation Triggers

Vafseo quarterly revenue growth flatlining or declining sequentially in 2026.
Auryxia quarterly revenues falling below $20 million faster than Vafseo can scale.
Failure to initiate the AKB-097 Phase 2 basket trial by the end of 2026.
Cash runway dropping below 12 months without a clear path to non-dilutive funding.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.